Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for RenovoRx, Inc. (RNXT : NSDQ)

• Company Description    RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $1.29 Daily Weekly Monthly 20 Day Moving Average: 474,891 shares Shares Outstanding: 45.13 (millions) Market Capitalization: $58.22 (millions) Beta: 0.98 52 Week High: $2.59 52 Week Low: $0.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.21% -22.40% 12 Week 37.06% 33.71% Year To Date 53.55% 35.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2570 West El Camino Real Suite 640 - Mountain View,CA 94040 USA ph: 650-284-4433 fax: 650-397-4433 renovorx@kcsa.com http://www.renovorx.com

• General Corporate Information    Officers Shaun R. Bagai - Chief Executive Officer; Director Ramtin Agah - Executive Chairman and Chief Medical Officer Mark Voll - Chief Financial Officer Laurence J. Marton - Director Una S. Ryan - Director Peer Information RenovoRx, Inc. (CORR.) RenovoRx, Inc. (RSPI) RenovoRx, Inc. (CGXP) RenovoRx, Inc. (BGEN) RenovoRx, Inc. (GTBP) RenovoRx, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75989R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 45.13 Most Recent Split Date: (:1) Beta: 0.98 Market Capitalization: $58.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.47 Price/Cash Flow: - Price / Sales: 29.46 EPS Growth vs. Year Ago Period: 37.50% vs. Previous Quarter: 37.50% Sales Growth vs. Year Ago Period: 115.40% vs. Previous Quarter: 61.46% ROE 09/30/26 - - 06/30/26 - -135.11 03/31/26 - -135.03 ROA 09/30/26 - - 06/30/26 - -101.91 03/31/26 - -101.92 Current Ratio 09/30/26 - - 06/30/26 - 5.74 03/31/26 - 7.15 Quick Ratio 09/30/26 - - 06/30/26 - 5.53 03/31/26 - 6.95 Operating Margin 09/30/26 - - 06/30/26 - -576.82 03/31/26 - -802.69 Net Margin 09/30/26 - - 06/30/26 - -621.71 03/31/26 - -823.98 Pre-Tax Margin 09/30/26 - - 06/30/26 - -621.71 03/31/26 - -823.98 Book Value 09/30/26 - - 06/30/26 - 0.20 03/31/26 - 0.25 Inventory Turnover 09/30/26 - - 06/30/26 - 1.01 03/31/26 - 1.51 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©